PL381730A1 - Oczyszczony preparat bakteriofagowy, sposób jego otrzymywania i zastosowania - Google Patents

Oczyszczony preparat bakteriofagowy, sposób jego otrzymywania i zastosowania

Info

Publication number
PL381730A1
PL381730A1 PL381730A PL38173007A PL381730A1 PL 381730 A1 PL381730 A1 PL 381730A1 PL 381730 A PL381730 A PL 381730A PL 38173007 A PL38173007 A PL 38173007A PL 381730 A1 PL381730 A1 PL 381730A1
Authority
PL
Poland
Prior art keywords
obtaining
manner
application
bacteriophage preparation
purified bacteriophage
Prior art date
Application number
PL381730A
Other languages
English (en)
Other versions
PL212099B1 (pl
Inventor
Tomasz Lipiński
Andrzej Gamian
Ewa Zuziak
Agnieszka Korzeniowska-Kowal
Andrzej Górski
Original Assignee
Instytut Immunologii i Terapii Doświadczalnej PAN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Immunologii i Terapii Doświadczalnej PAN filed Critical Instytut Immunologii i Terapii Doświadczalnej PAN
Priority to PL381730A priority Critical patent/PL212099B1/pl
Priority to EP08712679.3A priority patent/EP2117568B1/en
Priority to DK08712679.3T priority patent/DK2117568T3/en
Priority to US12/449,418 priority patent/US9255251B2/en
Priority to PCT/PL2008/000013 priority patent/WO2008097115A1/en
Priority to PL08712679T priority patent/PL2117568T3/pl
Publication of PL381730A1 publication Critical patent/PL381730A1/pl
Publication of PL212099B1 publication Critical patent/PL212099B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL381730A 2007-02-09 2007-02-09 Oczyszczony preparat bakteriofagowy, sposób jego otrzymywania i zastosowanie PL212099B1 (pl)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL381730A PL212099B1 (pl) 2007-02-09 2007-02-09 Oczyszczony preparat bakteriofagowy, sposób jego otrzymywania i zastosowanie
EP08712679.3A EP2117568B1 (en) 2007-02-09 2008-02-08 Purified bacteriophage, its preparation and application
DK08712679.3T DK2117568T3 (en) 2007-02-09 2008-02-08 Purified bacteriophage, its preparation and use
US12/449,418 US9255251B2 (en) 2007-02-09 2008-02-08 Purified bacteriophage, its preparation and application
PCT/PL2008/000013 WO2008097115A1 (en) 2007-02-09 2008-02-08 Purified bacteriophage, its preparation and application
PL08712679T PL2117568T3 (pl) 2007-02-09 2008-02-08 Oczyszczony bakteriofag, jego otrzymywanie i zastosowanie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL381730A PL212099B1 (pl) 2007-02-09 2007-02-09 Oczyszczony preparat bakteriofagowy, sposób jego otrzymywania i zastosowanie

Publications (2)

Publication Number Publication Date
PL381730A1 true PL381730A1 (pl) 2008-08-18
PL212099B1 PL212099B1 (pl) 2012-08-31

Family

ID=39495222

Family Applications (2)

Application Number Title Priority Date Filing Date
PL381730A PL212099B1 (pl) 2007-02-09 2007-02-09 Oczyszczony preparat bakteriofagowy, sposób jego otrzymywania i zastosowanie
PL08712679T PL2117568T3 (pl) 2007-02-09 2008-02-08 Oczyszczony bakteriofag, jego otrzymywanie i zastosowanie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL08712679T PL2117568T3 (pl) 2007-02-09 2008-02-08 Oczyszczony bakteriofag, jego otrzymywanie i zastosowanie

Country Status (5)

Country Link
US (1) US9255251B2 (pl)
EP (1) EP2117568B1 (pl)
DK (1) DK2117568T3 (pl)
PL (2) PL212099B1 (pl)
WO (1) WO2008097115A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009535942A (ja) * 2006-04-27 2009-10-01 レイスパン コーポレーション メタマテリアル構造に基づくアンテナ、デバイス、及びシステム
US7592957B2 (en) * 2006-08-25 2009-09-22 Rayspan Corporation Antennas based on metamaterial structures
WO2008115881A1 (en) * 2007-03-16 2008-09-25 Rayspan Corporation Metamaterial antenna arrays with radiation pattern shaping and beam switching
TWI376838B (en) * 2007-10-11 2012-11-11 Tyco Electronics Services Gmbh Single-layer metallization and via-less metamaterial structures
PL213166B1 (pl) * 2008-10-29 2013-01-31 Inst Immunologii I Terapii Doswiadczalnej Polskiej Akademii Nauk Sposób otrzymywania farmakologicznej stabilnej formy zliofilizowanych aktywnych preparatów oczyszczonych bakteriofagów
PL212796B1 (pl) * 2008-11-07 2012-11-30 Inst Immunologii I Terapii Doswiadczalnej Pan Diagnostyczny preparat immunologiczny oraz jego zastosowanie
GB2466177A (en) * 2008-12-03 2010-06-16 Arab Science & Technology Found Bacteriophage selection and breeding
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
CA2901690A1 (en) 2014-08-27 2016-02-27 The Governors Of The University Of Alberta Bacteriophage-based biosensor for microbial detection
RU2613423C1 (ru) * 2015-12-28 2017-03-16 Евгений Олегович Рубальский Способ получения бактериофага
CN107893058A (zh) * 2017-11-20 2018-04-10 大连雅立峰生物制药有限公司 一种去除疫苗制品中内毒素的方法
CN109593728A (zh) * 2018-11-17 2019-04-09 菲吉乐科(南京)生物科技有限公司 一种噬菌体絮凝剂及其在发酵后处理工艺中的应用
EP4038183B1 (en) * 2019-10-01 2025-03-26 Adaptive Phage Therapeutics, LLC Method for purification of bacteriophage particles
CN112175915B (zh) * 2020-10-12 2022-11-18 上海市公共卫生临床中心 一种噬菌体制剂中内毒素的去除方法及应用
CN116987577B (zh) * 2023-09-27 2024-11-08 深圳国家感染性疾病临床医学研究中心 一种低内毒素噬菌体制剂的制备方法及其制备系统
CN118620846B (zh) * 2024-03-25 2024-12-03 武汉格瑞农生物科技有限公司 一株针对耐药豚鼠气单胞菌的噬菌体及其在水产养殖中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589591A (en) * 1986-07-03 1996-12-31 Advanced Magnetics, Inc. Endotoxin-free polysaccharides
GB2327945A (en) * 1997-07-31 1999-02-10 Medeva Europ Ltd Removal of endotoxin from vaccines
CA2304123A1 (en) * 2000-04-19 2001-10-19 Mount Sinai Hospital Antibacterial therapy for multi-drug resistant bacteria
PL354822A1 (pl) * 2002-06-30 2004-01-12 Instytut Immunologii i Terapii Doświadczalnej PANwe Wrocławiu Sposób otrzymywania oczyszczonych preparatów bakteriofagowych oraz nowe zastosowania polisacharydu lub jego estryfikowanej pochodnej
CA2537725A1 (en) * 2003-09-03 2005-03-31 Intralytix, Inc. Method for vaccination of poultry by bacteriophage lysate

Also Published As

Publication number Publication date
US9255251B2 (en) 2016-02-09
EP2117568A1 (en) 2009-11-18
EP2117568B1 (en) 2016-08-03
PL2117568T3 (pl) 2017-01-31
PL212099B1 (pl) 2012-08-31
US20110008873A1 (en) 2011-01-13
WO2008097115A1 (en) 2008-08-14
DK2117568T3 (en) 2016-11-21

Similar Documents

Publication Publication Date Title
PL2117568T3 (pl) Oczyszczony bakteriofag, jego otrzymywanie i zastosowanie
IL210722A0 (en) Benzazepine derivatives, compositions comprising the same and uses thereof
SG10201401415QA (en) Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof
ZA201000588B (en) Improved pharmaceutical-coated medical products,the production thereof and the use thereof
IL241634A0 (en) History of benzodiazepines, preparations containing them and their uses
IL216254A (en) Compounds, pharmaceutical compositions and their uses
IL220625A (en) Isoindolinone compounds, preparations containing them and their uses
IL254218A0 (en) Pipedrine-bridged compounds of the quinoxaline-converted type and their use
IL211400A0 (en) Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
EP2307344A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, PREPARATION AND USE THEREOF
GB2451750B (en) Modified bacteriophage
ZA201000468B (en) Therapeutic compositions and the use thereof
EP2192122A4 (en) DITHIOLOPYRROLON COMPOUNDS, THEIR PREPARATION AND THEIR USE
PL383867A1 (pl) Sposób otrzymywania 4-N-furfurylocytozyny, kompozycja antystarzeniowa oraz zastosowanie 4-N-furfurylocytozyny do wytwarzania kompozycji antystarzeniowej
PL381556A1 (pl) Sposób otrzymywania modyfikowanych (poli)siloksanów
PL383170A1 (pl) Sposób otrzymywania preparatu wapniowego
PL382914A1 (pl) Nowe sililopodstawione 1,2-alkiny oraz sposób otrzymywania sililopodstawionych 1,2-alkinów
PL381142A1 (pl) Sposób otrzymywania glicydolu
PL383630A1 (pl) Nowy propionian S-(-)-3,5,5-trimetylocykloheks-2-enylu i sposób jego otrzymywania
PL382237A1 (pl) Nowe germylopodstawione 1, 2-alkiny oraz sposoby otrzymywania germylopodstawionych 1, 2-alkinów
PL383161A1 (pl) N-N-dialkilowe pochodne 2-amino-2-deoksy-D- glukitolo-6- fosforanu i sposób ich otrzymywania
EP2117313A4 (en) PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEM
PL381879A1 (pl) Postać preparatu farmaceutycznego oraz sposób jej otrzymywania
PL387384A1 (pl) Nowy związek 2-hydroksy-4-metylo-9-oksabicyklo [4.3.0] nonan-8-on i sposób jego otrzymywania
PL387385A1 (pl) Nowy związek 2-hydroksy-5, 5-dimetylo-9-oksabicyklo [4.3.0] nonan-8-on i sposób jego otrzymywania